A stochastic optimization approach for the design of individualized dosage regimens

AIChE Journal

Volumn 59, Issue 9, 2013, Pages 3296-3307

  Laínez Aguirre, José M ^a   Reklaitis, Gintaras V ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Dosage regimen individualization; MINLP; NLP; Pharmacometrics; Stochastic optimization; Uncertainty characterization

Indexed keywords

DOSAGE REGIMEN; MINLP; NLP; PHARMACOMETRICS; STOCHASTIC OPTIMIZATIONS; UNCERTAINTY CHARACTERIZATION;

BAYESIAN NETWORKS; DRUG DOSAGE; INFERENCE ENGINES; PROBABILITY DISTRIBUTIONS; RISK PERCEPTION; STOCHASTIC MODELS; STOCHASTIC SYSTEMS;

OPTIMIZATION;

EID: 84881669349     PISSN: 00011541     EISSN: 15475905     Source Type: Journal    
DOI: 10.1002/aic.14100     Document Type: Article

References (34)

1. Bogle IDL, Allen R, Sumner T. The role of Computer Aided Process Engineering in physiology and clinical medicine. Comput Chem Eng. 2010;34:763-769.
2. Neely M, Jelliffe R. Practical, Individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J Clin Pharmacol. 2010;50:842-847.
3. Jelliffe R, Schumitzky A, Guilder MV, Liu M, Hu L, Maire P, Gomis P, Barbaut X, Tahani B. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit. 1993;15:380-393.
4. Mehvar R. Pharmacokinetic-based design and modification of dosage regimens. Am J Pharm Edu. 1998;62:189-195.
5. Salinger DH, McCune JS, Ren AG, Shen DD, Slattery JT, Phillips B, McDonald GB, Vicini P. Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin Cancer Res. 2006;12(16):4888-4898.
6. McCune JS, Batchelder A, Guthrie KA, Witherspoon1 R, Appelbaum FR, Phillips B, Vicini P, Salinger DH, McDonald GB. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther. 2009;85(6):615-622.
7. Laínez JM, Blau G, Mockus L, Orçun S, Reklaitis GV. Pharmacokinetic based design of individualized dosage regimens using a Bayesian approach. Ind Eng Chem Res. 2011;50(9):5114-5130.
8. Bayard D, Milman M, Schumitzky A. Design of dosage regimens: a multiple model stochastic control approach. Int J Bio-Med Comput. 1994;36:103-115.
9. Ji S, Zeng Y, Wu P, Lee E. Weighted target interval stochastic control methods with global optimization and their applications in individualizing therapy. J Pharmacokinet Pharmacodyn. 2007;34:433-449.
10. Florian JA Jr, Eiseman JL, Parker RS. Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model. Comput Biol Med. 2008;38(3):339-347.
11. Noble SL, Sherer E, Hannemann RE, Ramkrishna D, Vik T, Rundell AE. Using adaptive model predictive control to customize maintenance therapy chemotherapeutic dosing for childhood acute lymphoblastic leukemia. J Theor Biol. 2010;264(3):990-1002.
12. Sopasakis P, Sarimveis H. An integer programming approach for optimal drug dose computation. Comput Methods Programs Biomed. 2012;108(3):1022-1035.
13. Metropolis N, Rosenbluth AW, Rosenbluth MN, Teller AH, Teller E. Equation of state calculations by fast computing machines. J Chem Phys. 1953;21(6):1087-1092.
14. Blau G, Lasinski M, Orcun S, Hsu SH, Caruthers J, Delgass N, Venkatasubramanian V. High fidelity mathematical model building with experimental data: a Bayesian approach. Comput Chem Eng. 2008;32(4-5):971-989.
15. Bishop CM. Pattern Recognition and Machine Learning. New York, NY: Springer Science, 2006.
16. Cuthrell JE, Biegler LT. On the optimization of differential-algebraic process systems. AIChE Journal. 1987;33(8):1257-1270.
17. Mulvey JM, Vanderbei RJ, Zenios SA. Robust optimization of large-scale systems. Operation Res. 1995;43:264-281.
18. Rockafellar RT, Uryasev S. Optimization of conditional value-at-risk. J Risk. 2000;2:21-41.
19. Eppen GD, Martin RK, Schrage L. A scenario approach to capacity planning. Operation Res. 1989;37:517-527.
20. Barbaro AF, Bagajewicz M. Managing financial risk in planning under uncertainty. AIChE J. 2004;50:963-989.
21. Heiss F, Winschel V. Likelihood approximation by numerical integration on sparse grids. J Econometrics. 2008;144(1):62-80.
22. Rosenthal RE. GAMS-A User's Guide. Washington, DC: GAMS Development Corporation, 2011.
23. Drud A. CONOPT. ARKI Consulting & Development A/S, Bagsvaerd, Denmark, 2011.
24. ARKI Consulting & Development. SBB. ARKI Consulting & Development A/S, Bagsvaerd, Denmark, 2011.
25. Genz A, Keister BD. Fully symmetric interpolatory rules for multiple integrals over infinite regions with Gaussian weight. J Comput Appl Math. 1996;71:299-309.
26. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2008.
27. Soetaert K, Petzoldt T, Setzer RW. Solving differential equations in R. R J. 2010;2:5-15.
28. Eddelbuettel D, François R. Rcpp: Seamless R and C++ Integration. J Stat Software. 2011;40:1-18.
29. Sklyar O. Inline: Inline C, C++, Fortran function calls from R. Available at: http://cran.r-project.org/web/packages/inline/index.html. 2011, Last accessed September, 2012.
30. Urban T, Brown C, Castro R, Shah N, Mercer R, Huang Y, Brett C, Burchard E, Giacomini K. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008;83(3):416-421.
31. ARUP-Laboratories. ARUP's Laboratory Test Directory-Gabapentin. Available at: http://www.aruplab.com/guides/ug/tests/0090057.jsp, 2010, Last accessed September, 2012.
32. García LL, Shihabi ZK, Oles K. Determination of gabapentin in serum by capillary electrophoresis. J Chromatogr B. 1995;669:157-162.
33. Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI, Anasetti C, Appelbaum FR. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol. 1996;14:1484-1494.
34. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101(5):2043-2048.